Incyte Licenses Disputed Microarray Technology to American Home

Oct 03, 2000

NEW YORK, Oct 3 – In the midst of an intellectual property battle with Affymetrix (Nasdaq: AFFX) over a non-PCR based RNA technology that researchers use in microarray-based gene expression analysis, Incyte Genomics (Nasdaq: INCY) said Tuesday it had licensed the related patents to American Home Products (NYSE: AHP) for internal use with Affy’s GeneChips.

AHP, a Madison, NJ-based pharmaceutical company, is also a subscriber to Incyte’s LifeSeq gene sequence database.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu